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Abstract: (249 words) 
Introduction: Research on associations between medication use during pregnancy and congenital 
anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly 
registries do not have optimal information on medicine exposure, in contrast to prescription 
databases. Linkage of prescription databases to the congenital anomaly registries is a potentially 
effective method of obtaining accurate information on medicine use in pregnancies and the risk of 
congenital anomalies. 
Methods:  We linked data from primary care and prescription databases to five EUROCAT congenital 
anomaly registries. The linkage was evaluated looking at linkage rate, characteristics of linked and 
non-linked cases, first trimester exposure rates for six groups of medicines according to the 
prescription data and information on medication use registered in the congenital anomaly databases 
and agreement of exposure.  
Results: Of the 52,619 cases registered in the congenital anomaly databases, 26,552 cases could be 
linked. The linkage rate varied between registries over time and by type of birth. The first trimester 
exposure rates and the agreements between the databases varied for the different medicine groups. 
Information on anti-epileptic drugs, and insulins and analogue medicine use recorded by congenital 
anomaly registries was of good quality. For SSRIs, anti-asthmatics, antibacterials for systemic use, 
and gonadotropins and other ovulation stimulants, the recorded information was less complete. 
Conclusion: Linkage of primary care or prescription databases to congenital anomaly registries 
improved the quality of information on maternal use of medicines in pregnancy, especially for 
medicine groups which are less fully registered in congenital anomaly registries. 
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Key  points: 
• Linkage of primary care or prescription databases to congenital anomaly registries improved 
the quality of information on maternal use of medicines in pregnancy. 
•  The quality improved especially for medicine groups which are less fully registered in 
congenital anomaly registries, like SSRIs, anti-asthmatics, antibacterials for systemic use, and 
gonadotropins and other ovulation stimulants.  
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1.  Introduction 
   Medicines are commonly used during pregnancy: approximately 80% of all women use at 
least one medicine during pregnancy [1]. Although the use of some medicines is unavoidable for 
serious or chronic conditions, foetal exposure may increase the risk of a congenital anomaly (CA). 
One example is the anti-epileptic medication valproic acid, which increases the risk of having a child 
with spina bifida if taken in the first trimester of pregnancy [2]. However, little is known regarding 
the teratogenic effects of many medicines. Research on possible associations between medicine use 
during pregnancy and CA is of great importance for assessing the safe use of a medicine in 
pregnancy. Since CA are rare outcomes, and medicine needs to be analysed in specific groups or as 
specific drugs, we need to study large datasets with accurate and detailed information on the type 
and timing of medicine exposure in pregnancy and the type of a possibly related CA.  
  The European Surveillance of Congenital Anomalies (EUROCAT) network consists of 43  
population-based registries set up for the epidemiological surveillance of CA; the network covers 
29% of all births in Europe [3, 4, 5].
 
These registries hold information on foetuses and children with 
CA, and associated factors such as maternal medicine use in pregnancy. Most of the registries 
retrieve information on first trimester maternal medicine use from medical files, which may be 
limited and incomplete [6].
 
  
  Prescription databases, which are increasingly being used to explore associations between 
medicine use in pregnancy and CA[7-10],
 
contain more complete information on medicine use than 
CA registries, and prescribing information is prospectively collected. Given the quality of information 
on medicine exposure that is recorded in both CA registries and prescription databases, linking 
prescription databases to the EUROCAT CA registries is a potentially effective method of obtaining 
accurate information on medicine use in pregnancies that were complicated by fetal CA. 
  In this study we linked  administrative prescription databases with five CA registries. We 
present the results for six selected groups of medicines: anti-epileptic medicines (Anatomical 
Therapeutic Chemical (ATC) code[11] N03A), insulins and analogues (A10A), SSRIs (N06AB), anti-
asthmatics (R03), antibacterials for systemic use (J01), and gonadotropins and other ovulation 
stimulants (G03G). 
 This research was embedded in the EUROmediCAT project [12],
 
 which stimulates the 
collaboration of health care databases and EUROCAT registries. It was a Seventh Framework 
Programme study funded by the European Union. 
 
2. Methods 
In this study, prescription/ primary care databases were linked to five EUROCAT CA registries: 
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• Wales - the general practitioner data in the Secure Anonymised Information Linkage (SAIL) 
Databank [13,14] was linked to the Welsh congenital anomaly registry (CARIS);  
• Norway - Reseptregisteret (Norwegian Prescription Database, NorPD) was linked to the 
Medical Birth Registry from Norway (MBRN)[15,16];  
• Denmark, Odense - Lægemiddelstatistikregisteret (Danish National Prescription 
Registry)[17]
 
was linked to the congenital anomaly registry of Odense, Denmark; 
• Italy, Emilia Romagna - Emilia Romagna Prescription Database (ERPD)[18]
 
was linked to 
Emilia Romagna congenital anomaly registry (IMER), Italy; 
• Italy, Tuscany - Assistenza Farmaceutica Territoriale (AFT, Pharmaceutical Territorial 
Assistance) and Farmaci a Erogazione Diretta (FED, Medicine Directly Dispensed by the 
Health System) [19]
 
were linked to the congenital anomaly registry of Tuscany, Italy (RTDC). 
 
The CA registries collect data on foetuses and infants with CA, including live births (LB), foetal 
deaths (FD) ≥ 20 weeks of gestational age (including stillbirths), and terminations of pregnancy for 
foetal anomaly (TOPFA). Information on date of birth, gestational age at birth, maternal age, long-
term diseases, maternal medicines and disease exposures during pregnancy are also collected. The 
first trimester of pregnancy is defined according to the EUROCAT Guide[20] as the period from the 
first day of Last Menstrual Period (LMP) up to 12 completed weeks of gestation [day 0 to day 83]. 
  The primary care or prescription databases involved in our linkage effort are population-
based administrative databases that contain data on medicines prescribed and/or dispensed. In the 
linked prescription data, the first trimester was defined as the period from the first day of LMP as 
recorded in the CA database up to 14 completed weeks of gestation [day 0 to day 97]. If the LMP 
was unknown, it was calculated as the date of birth of the child minus the gestational age at birth as 
recorded in the CA database. If the gestational age at birth was unknown, a standardized length of 
280 days (40 weeks) for live births and 224 days (32 weeks) for still births was used. If the gestational 
age was unknown for a TOPFA case, the average age for TOPFA’s for the respective registry across 
the whole of the included time period was used. Characteristics of the primary care/prescription 
databases and the CA registries have been described in detail elsewhere[4,6,21,22]. Table 1 
summarizes the birth years, the number of CA cases registered in the study period, the registry 
sources for maternal medicine use, whether the medicine recorded in the CA data was based on the 
first trimester only or for the whole pregnancy and the proportion of cases with at least one 
medicine recorded in the CA database.   
 We applied a distributed database model, in which the linkage was performed locally for all 
registries and the linked datasets were kept locally [23].
 
The linkage was performed by matching 
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identification numbers and/or maternal characteristics in both the primary care/prescription and the 
CA databases. For CA cases identified in the primary care/prescription databases, the information 
held on medicine use was added to the information in the CA registry. Details of the linkage process 
have been described elsewhere [24].
 
 
 An Access-based software module, the Linkage Data Management Program (LDMP), was 
developed for this project and used to ensure validated datasets. The LDMP was used to import and 
export data, validate data, and generate tables for evaluation and analyses. The use of the LDMP 
ensured the compatibility of anomaly subgroups and medicine groups among the participating 
registries and allowed tables to be generated in a uniform way. To evaluate the linkage effort, the 
participating registries provided tables generated by LDMP. Since the Danish regulations do not 
allow external software to be used on their server, Odense, Denmark was not able to import their 
data via the LDMP. They generated the aggregated tables locally and generated the tables manually, 
using the same selection criteria and definitions as in the LDMP.  
In the analyses cases that met the EUROCAT case definition were included: cases with major CA 
defined by the Q-chapter of the International Classification of Diseases 10
th
 revision (ICD10), or in 
the range 740-759 of ICD9, and a very limited set of conditions not included in the Q chapter [20].
 
 
Cases with isolated minor anomalies were excluded from the EUROCAT case definition.  
Using the LDMP, each registry evaluated the linkage on the following aspects: 
• Linkage success, defined as the proportion of cases in the CA database that could be linked 
to the primary care/prescription data. 
• Comparison of the linked and non-linked cases: since not all the cases could be linked, we 
considered it relevant to compare both groups on year of birth and type of birth. A Chi
2 
test 
was performed for both factors to determine the statistical significance. If 20% of the cells in 
the contingency table had less than five observations, a Fisher Exact test was performed 
instead of the Chi
2 
test. The statistical tests were performed in PASWStatistics 22 (SPSS Inc., 
IBM, Chicago, IL, USA). 
• Comparison of data on first trimester medicine use: the ‘first trimester exposures rates’ and 
the ‘agreement of exposure’ were calculated as described in figure 1 to compare the data. 
These factors were calculated for six groups of medicines: anti-epileptic medicines, insulins 
and analogues, SSRIs, anti-asthmatics, antibacterials for systemic use, and gonadotropins 
and other ovulation stimulants. The agreement according to the primary care/prescription 
data may be influenced by the definition of first trimester exposure (date of prescription in 
period 0-97 days), therefore we also calculated the agreement using a broader 1
st
 trimester 
definition (-31 to +97 days after LMP). 
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3. Results 
  The five CA databases included 52,619 cases in total, of which 65.7% (n=34,547) could be 
linked. The proportion of cases that could be linked ranged from 31.7% in Wales (where 40% of the 
primary care practices contribute prescription data to the voluntary SAIL database) to 100% in 
Odense, Denmark. Of the 34,547 registered cases that were linked to prescription databases, 26,552 
(76.9%) met the EUROCAT case definition as described in the Methods section (Table 2a).  
The linked and non-linked EUROCAT cases  were compared for year of birth and type of birth 
for the registries with less than 100% linkage success( table 2b). There was a significant difference 
between the linked and non-linked cases for all registries in year of birth. For Wales, Emilia-Romagna 
and Tuscany, the rate of linked cases increased over time, while the number of linked cases 
decreased over time in Norway. For type of birth, there were no differences between linked and 
non-linked cases for Wales and Norway. For Emilia Romagna, TOPFA cases were only seen in the 
non-linked group while, for Tuscany, there were fewer live births (74.0% vs. 86.2%), but more TOPFA 
cases (25.1% vs. 12.6%) in the linked group. 
 The first trimester exposure rates according to the CA data and the primary 
care/prescription database are shown in Table 3. For the anti-epileptic medicines and the insulins 
and analogues, there were small, but potentially clinically important differences between the first 
trimester exposure rates based on the CA registries and the primary care or prescription database. 
The first trimester exposure rates for anti-asthmatics also revealed small differences between those 
recorded in the CA registries and in the primary care or prescription database per registry, except for 
Tuscany. For Tuscany, the first trimester exposure rate recorded in the prescription database was 
more than six times higher than the rate recorded in the CA registry. For the SSRIs the first trimester 
exposure rates recorded in the primary care or prescription database were 2-3 times higher than the 
rates recorded in the CA registries for Wales, Emilia Romagna and Tuscany. For antibacterials for 
systemic use, the first trimester exposure rates recorded in the primary care or prescription 
databases was much higher than the rates in the CA registries. Furthermore, there was a wide 
variation over the registries: for the CA registries, the rates ranged from 1.84% (Tuscany) to 10.12% 
(Emilia Romagna) while for the primary care or prescription databases the rates ranged from 9.84% 
(Norway) to 15.52% (Emilia Romagna). The first trimester exposure rates for the gonadotropins and 
other ovulation stimulants were also higher in the prescription databases, except for Wales. 
 The agreement according to the primary care/prescription data and the agreement 
according to the CA data for the first trimester is shown in Table 4a. For the anti-epileptic medicines 
and insulins and analogues, which are both used for long-term conditions, the agreement between 
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both databases was generally relatively high. The SSRIs and anti-asthmatics, which are also used in 
long-term conditions, showed a lower agreement between the two databases. Medicines for 
occasional use, such as antibacterials for systemic use, and gonadotropins and other ovulation 
stimulants, showed a relatively low agreement between the databases. Extending the time period by 
including the month before the first trimester did not affect the findings on anti-epileptic medicines 
and insulins and analogues to a large extent, but the agreement according to the CA data was 
increased for SSRIs and anti-asthmatics for some of the registries (table 4b). 
4. Discussion 
We linked administrative databases to five CA registries and evaluated the results of the 
linkage for six types of common medicines. The linkage success varied between registries over time 
and, for the Italian registries, by type of birth. The first trimester exposure rates and the agreements 
between the databases varied for the different medicine groups. In general, information on anti-
epileptic medicines, and insulins and analogue medicine use recorded by CA registries was of good 
quality. For SSRIs, anti-asthmatics, antibacterials for systemic use, and gonadotropins and other 
ovulation stimulants, the recorded information was less complete. 
 A major challenge in using prescription data is linking it to all the cases of CA, 
irrespective of pregnancy outcome. For Norway and Odense, Denmark, linkage was possible for 
most cases, as the linkage used personal ID numbers, while the linkage success was lower for the 
other registries. In Wales, general practitioners (GPs) contribute to SAIL on a voluntary basis, 
currently 40% of the GPs contribute and although this percentage is increasing,  it reduces the 
number of Welsh cases that could be linked. For Emilia Romagna, the TOPFA cases could not be 
included in the linkage, because the CA registry does not have ID numbers for the TOPFA cases or 
their mothers due to privacy regulations. As a result, the linked cases are biased towards the less 
severe cases there. In Tuscany, an ID number for the mother was only available for 52% of the 
TOPFA cases.  Therefore, one should be aware that if not all cases can be linked, there may be some 
bias in the results reported or the linked dataset may not be suitable to analyse a possible 
association between medication use and severe anomalies that result frequently in terminations of 
pregnancy.  
 Medicines prescribed or dispensed before the first trimester were not included in the first 
trimester definition of the primary care or prescription databases. It is possible that these medicines, 
although prescribed earlier, were also taken in the first trimester and therefore registered in the CA 
registry. Technically there is a difference in the definition of the first trimester between the primary 
care or prescription databases and the CA registries. However, we expect the influence on the first 
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trimester exposure rates to be minimal, since the CA registries collect information on medicine use 
mainly from medical files (except Tuscany) in which medicine use is recorded as ‘used in the first 
trimester’ rather than on a specific date. In addition, the Norwegian CA registry and Emilia Romagna 
includes information on medicine used during any time in pregnancy, not specifically during the first 
trimester. Therefore, misclassification of exposure cannot be ruled out; in particular for medicines 
prescribed or taken at the start or towards the end of the first trimester there may be disagreement 
between the information recorded in the CA data and the prescription data.  
 For Emilia Romagna, relatively low rates of agreement were found for medicines taken for 
long-term conditions. The registry has now changed their data sources for medicine exposures and 
has added prescription information as a data source. 
 In general, per registry, the anti-epileptic medicines and insulins and analogues showed 
small differences between the first trimester exposure rates recorded in the CA registries and the 
rates in the primary care or prescription databases. In addition, the agreements between the 
primary care/prescription databases and the CA registries were, in general, relatively high. This was 
expected, since these medicines are prescribed for long-term conditions and used on a regular, daily 
basis; they are therefore well recorded in both medical files and prescription databases. However, 
we noted 98 cases in which insulin (54) and anti-epileptics (44) were prescribed in primary care or 
prescription database, but not recorded in or abstracted from the medical files, which are the main 
data source for the CA registries. Such omissions from the medical records could have serious clinical 
consequences, unless more accurate histories were taken on admission for delivery. 
 For the anti-asthmatics, small differences were found between the first trimester exposure 
rates recorded in the CA registries and the primary care or prescription database per registry. 
However, the agreements between the primary care/prescription databases and the CA registries 
were, in general, relatively low. The most plausible explanation for this is that some anti-asthmatics 
are often taken ‘as necessary’. It is possible that they were dispensed before the first trimester, and 
were therefore not present in the prescription database as a first trimester prescription, but that 
they were indeed used in the first trimester and therefore recorded in the CA registry. Extending the 
relevant period with the month before pregnancy, increased the agreement for anti-asthmatics and 
SSRIs.
 
This emphasizes that the time frame used in the definition of the first trimester may differ for 
medicines depending on prescribing characteristics. Other explanations for low agreement could be 
that the prescribed medicines were not taken (non-compliance) or that the medicines were taken, 
but their use was not recorded. Medicines may not be recorded in medical files for several reasons: 
women may forget; the midwife may not ask the woman about medicine use when taking the initial 
medical history, or the question may be asked in a perfunctory manner, so that the woman does not 
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realise the importance of an accurate medical history; women may be uncertain of the starting date 
of their first trimester; medication use may be mentioned but not recorded in the medical file; or the 
medicine was prescribed after the first antenatal visit and therefore not recorded in the medical file. 
Some CA registry records did not give the full name of the medicines taken, so no ATC code could be 
matched to the prescription database: for example, if the woman cannot name her specific 
medicine, just ‘taking antidepressant’ may be recorded. When no information is found in medical 
records on maternal medication use, registries may either interpret this as ‘no medication taken’ or 
‘medication use unknown’. The use of administrative data may overcome this problem. 
 For the SSRIs, the first trimester exposure rates recorded in the primary or prescription 
database were 2-3 times higher than the rates recorded in some CA registries. Furthermore, SSRIs 
had a relatively low agreement according to the primary care/prescription data. The high rate of 
non-reporting of antidepressants suggests that records might be biased by the stigma surrounding 
mental illness. This may lead to either non-adherence with prescribed regimens or non-reporting. 
Reporting of antiepileptic prescriptions (often for mental illness) may have been similarly affected. 
 For the antibacterials for systemic use, the rates found in the primary care or prescription 
databases were much higher than the rates in CA registries and there were differences between the 
registries. The agreements according to both the primary care/prescription databases and the CA 
registries were, in general, relatively low. It is likely that, by the time of their interviews with the 
midwife, some women had forgotten having a short course of antibacterial agents. The differences 
over the registries can be explained by differences in the prescribing behaviour seen between the 
regions.  
 For gonadotropins and other ovulation stimulants, rates in the primary care or prescription 
databases were generally higher than the rates in CA registries, whereas the agreements according 
to both the primary care/prescription database and the CA registries were, in general, relatively low. 
Since these medicines are used in fertility treatments and the prevention of miscarriages, non-
compliance is a less plausible explanation. The medicines were presumably used, but not recorded. 
For gonadotropins and other ovulation stimulants, it is also possible that the woman did not 
mention their use because she did not consider them as medicines, or she was concerned about 
possible stigmatisation. 
 In conclusion, we found that information on anti-epileptics, and insulins and analogues, was 
fairly complete in the CA registries, whereas for SSRIs, anti-asthmatics, antibacterials for systemic 
use, and gonadotropins and other ovulation stimulants, the information was less complete. 
Therefore, the linkage held more added value for SSRIs, anti-asthmatics, antibacterials for systemic 
use, and gonadotropins and other ovulation stimulants. 
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 In our project, the linkage was performed locally for all registries and the linked datasets 
were kept locally, according to the distributed database model. This was necessary to comply with 
confidentiality regulations in Odense, Denmark, Norway and Wales, where linked data may not be 
sent outside the server. However, since large datasets are needed to study the safety of medicine 
use in pregnancy, the separate local datasets need to be combined for further studies on the risk of 
medicines in pregnancy; the ideal situation would be to collect and analyse such linked data in a 
central unit. 
 For this project we used data from prescription databases. In principle, prescription data 
contain the complete, prospectively recorded, medication history, except for Over-The-Counter 
(OTC) medication and medications dispensed in hospitals and private clinics. However, in Norway, 
the prescription database includes medicines dispensed to an individual (out-patient) who collects 
them at a hospital pharmacy, but it does not include medicines given to individuals who are in 
hospital (in-patients). Furthermore, the quality of prescription data is not affected by the woman’s 
recall or the accuracy of health care professionals who record medication use in medical files. 
 Nonetheless, this does not necessarily mean that medicines prescribed or dispensed are 
actually taken [25].
 
However, we know from a Dutch cross-sectional study that prescription data will 
most likely overestimate the exposure, but this overestimation seems to be minimal, which makes 
prescription records a reliable source for research into associations between medication use in 
pregnancy and CA [26]. 
 The information on amount and dosage prescribed was not available in a standard way 
(DDD) in our databases. Therefore, we could not include the duration of the prescription in our 
definition of exposure[21].
 
To improve the use of prescription data, information on the amount 
prescribed and the daily dose should be included in the administrative databases. In addition, more 
uniformity concerning data definitions ( ATC codes, medication grouping, first trimester definition) 
should also be taken into account to prevent bias. 
 In a previous Norwegian study, data of the NorPD and MBRN, which were also included in 
this study, were linked and compared by calculating the sensitivity, the specificity and the positive 
predictive value (PPV) of recorded medicine in the MBRN for the period 2004-2007, using NorPD as 
the “gold standard” [15]. It was possible to compare the Norwegian study’s ‘sensitivity values’ to our 
values of agreement according to the prescription database, and to compare the ‘PPV values’ to our 
values of agreement according to the CA registry. However, the Norwegian study did not provide 
data on gonadotropins and other ovulation stimulants specifically, while they did provide data on 
selective beta-2-adrenoreceptor agonists (ATC code R03AC) and glucocorticoids (ATC code R03BA) 
instead of anti-asthmatics in general (ATC code R03). We found the values of sensitivity and the 
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agreement according to the prescription data for Norway to be comparable. However, the values of 
the PPV were higher in the Norwegian study than the values we calculated for the agreement 
according to the CA registry for Norway. This difference may be related to the fact that the 
Norwegian study included all deliveries, while we only included deliveries with a CA in the offspring.  
 In another study, administrative data relating to all pregnancy events (which were classified 
as a birth, an ectopic pregnancy, or a termination of pregnancy) in Western Australia were linked to 
a national database of dispensed medicines for the period 2002-2005. This study had a high linkage 
rate of health and other data due to very few missed links (0.11%) and low permanent migration 
(2.7%), and the researchers found that a medicine had been dispensed to 28.0% of women who had 
a pregnancy event [27,28].
 
 
  
5. Conclusion 
We have described the linkage of primary care or prescription databases to CA registries and 
shown that this improves the quality of information on maternal use of medicines in pregnancy, 
especially for some medicine groups which are less fully registered in CA registries, like SSRIs, anti-
asthmatics, antibacterials for systemic use, and gonadotropins and other ovulation stimulants. 
However, if the prescribed medicine is not actually taken, the use of prescription data may lead to 
an overestimation of exposure. Possible selection bias towards specific types of CA in the linked 
cases needs further attention. 
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Figure 1. Data in the primary care/prescription databases and the CA databases  
 
 Prescription database 
+ – Total 
CA database + A  B  A+B 
– C  D C+D 
Total A+C  B+D A+B+C+D 
 
First trimester exposure rate according to CA registry data  
% of women exposed to medicine in the first trimester according to the CA registry  
(A+B)/(A+B+C+D) *100% 
 
First trimester exposure rate according to prescription data  
% of women exposed to medicine in the first trimester according to the prescription database  
(A+C)/(A+B+C+D) *100% 
 
Agreement of exposure according to the primary care/prescription data  
Number of women using medicine according to both CA registry and prescription database divided by the 
total number of women with medicine prescribed in the prescription database 
A/(A+C) *100% 
 
Agreement of exposure according to the CA data  
Number of women using medicine according to both CA registry and prescription database divided by the 
total number of women with medicine prescribed in the CA registry 
A/(A+B) *100% 
- The numbers per registry for each medicine are available on – 
http://www.euromedicat.eu/content/WP3%20Deliverable%2011%20Report.pdf  - 
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